From November 5 to 10, the 8th China International Import Expo (hereinafter referred to as "CIIE") was held at the National Exhibition and Convention Center in Shanghai. During the event, Sino Biopharm (1177.HK) reached a strategic cooperation with AstraZeneca (China) and MediTrust Health, focusing on the field of neoplasm treatment to inject new momentum into its own development through synergistic innovation and deep industrial integration. 

Innovative Payment Models to Enhance Drug Accessibility

How to bridge the "last mile" for innovative drugs to benefit patients is a key challenge currently facing the pharmaceutical industry. On November 7, Sino Biopharm signed a strategic cooperation agreement with Shanghai MediTrust Health Technology Group Co., Ltd. to carry out in-depth cooperation around "innovative drugs + commercial insurance", jointly exploring new models of integrating pharmaceuticals and insurance to help more patients access and afford high-quality medicines sooner. 

Mr. Tse Hsin, Executive Director and Senior Vice President of Sino Biopharm, stated at the signing ceremony that with changes in population structure and the deepening of medical insurance reform, commercial health insurance is becoming an important channel for innovative drugs to enter the market. Sino Biopharm is not only committed to developing more high-quality drugs that are "First-in-China, Best-in-Globe", but also hopes to solve the key challenges in realizing the value of innovative drugs, and become a builder and leader of the health ecosystem. 

As a leading multi-payment service platform for pharmaceuticals, MediTrust Health can efficiently connect the payment and healthcare service ends by leveraging its integrated payment model, extensive medical network, and digital intelligence capabilities. The two parties will continue to explore in areas such as artificial intelligence, data collaboration, and diversified payments, working together to accelerate the delivery of innovative therapies to benefit Chinese patients better and faster. 

Focusing on Lung Cancer Prevention and Treatment, Conducting Combination Therapy Research

Although targeted therapy and immunotherapy have made significant progress in recent years, lung cancer prevention and treatment still face challenges such as complex and diverse driver gene subtypes and drug resistance in some patients. Combination therapy, as an important direction to break through treatment bottlenecks, is becoming a focus of global lung cancer research. 

On November 7, Chia Tai Tianqing, a core enterprise of Sino Biopharm, signed a strategic cooperation framework agreement with AstraZeneca (China) for research on combination therapy for lung cancer, joining hands to explore a "China solution" in the field of lung cancer treatment. With clinical needs at its core, Chia Tai Tianqing has built a full industry chain layout covering small-molecule targeted drugs, large-molecule biologics, bispecific antibodies, and Antibody-Drug Conjugates (ADCs). Targeting key driver genes such as ALK, ROS1, KRAS G12C, and HER2, Sino Biopharm has successfully launched targeted drugs including Anluoqing^®, Anboni^®, Anfangning^®, and Hernexeos^®; for the broad-spectrum treatment needs of non-small cell lung cancer and small cell lung cancer, products like Fukewei^®, Andewei^®, and Annike^® have become common clinical options. 

In addition, Chia Tai Tianqing has a strong R&D pipeline, with several new small-molecule drugs including a fourth-generation EGFR inhibitor, EGFR PROTAC, a fourth-generation ALK inhibitor, KRAS G12D, pan-RAS, and pan-KRAS PROTAC; large-molecule products such as the EGFR/c-Met bispecific antibody TQB2922 and the bispecific antibody ADC TQB6411 are in advanced stages of development globally, covering the full-cycle needs of lung cancer treatment. This collaboration will fully leverage the R&D and clinical strengths of both parties to explore more combination therapy regimens, helping to improve the level of lung cancer prevention and treatment in China. 

Oral Targeted Drug Ushers in a New Era of Lung Cancer Treatment

On November 6, a China launch ceremony was held for Zongertinib Tablets (Hernexeos^®), jointly promoted in mainland China by Sino Biopharm and Boehringer Ingelheim, adding a significant highlight to the showcase of innovative achievements at the CIIE. As the world's first and only approved oral HER2 tyrosine kinase inhibitor for non-small cell lung cancer, the launch of Hernexeos^® marks the entry of HER2-mutant non-small cell lung cancer treatment in China into a new era of oral targeted drugs. 

Looking to the future, Sino Biopharm will leverage its domestic market advantages and R&D capabilities, working with global partners to contribute more Chinese wisdom to the development of the global pharmaceutical and health industry. 

Source: Boehringer Ingelheim Biopharmaceuticals (China), MediTrust Health, AstraZeneca (China)